MLYSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Mineralys Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$20.92+0.62 (+3.05%)
Close on Oct 19, 2026
- Market cap
- $1.77B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
100M of 88M shares
Institutional holders
226
36 new, 22 sold out
Net institutional buying
10M
In Q2 2026
Insider trades, 12 months
2 buys · 79 sales
Net sold $77.33M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Catalys Pacific Fund, LP | 8,002,738 | 10.10% | 13G (passive) amendment | Dec 31, 2025 |
| Rajeev Shah | 7,796,433 | 9.90% | 13D (active) amendment | Sep 4, 2025 |
| Srinivas Akkaraju | 6,346,194 | 8.20% | 13D (active) amendment | Sep 4, 2025 |
| Peter Kolchinsky | 6,287,597 | 9.90% | 13D (active) amendment | Mar 13, 2025 |
| FMR LLC | 5,017,509 | 6.30% | 13G (passive) | Dec 31, 2025 |
| Abigail P. Johnson | 4,461,689 | 5.10% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 4,113,657 | 5.20% | 13G (passive) | Dec 31, 2025 |
| TCG Crossover GP II, LLC | 2,470,265 | 5.00% | 13G (passive) amendment | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MLYS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Catalys Pacific, LLC | 7,903,838 | 8.94% | $213.25M | – | 92.94% |
| Ra Capital Management, L.P. | 7,692,750 | 8.70% | $207.55M | – | 1.80% |
| BlackRock, Inc. | 5,887,038 | 6.66% | $158.83M | +1,405,456 | 0.00% |
| Samsara BioCapital, LLC | 5,871,018 | 6.64% | $158.40M | – | 13.01% |
| FMR LLC | 4,511,689 | 5.10% | $121.73M | −349,415 | 0.01% |
| State Street Corp | 4,141,636 | 4.68% | $111.74M | +1,205,696 | 0.00% |
| Deerfield Management Company, L.P. (Series C) | 3,958,000 | 4.48% | $106.79M | New | 1.11% |
| Vanguard Capital Management LLC | 2,756,770 | 3.12% | $74.38M | +302,407 | 0.00% |
| Laurion Capital Management LP | 2,506,152 | 2.83% | $67.62M | +274,112 | 1.73% |
| Price T Rowe Associates Inc /Md/ | 2,262,476 | 2.56% | $61.04K | +919,163 | 0.01% |
| Orbimed Advisors LLC | 2,110,300 | 2.39% | $56.94M | +57,400 | 1.05% |
| Capital World Investors | 1,997,607 | 2.26% | $53.90M | +1,599,428 | 0.01% |
| Armistice Capital, LLC | 1,736,000 | 1.96% | $46.84M | +560,000 | 0.57% |
| Troluce Capital Advisors LLC | 1,728,753 | 1.96% | $46.64M | +1,073,753 | 4.80% |
| Nantahala Capital Management, LLC | 1,640,962 | 1.86% | $44.27M | +745,481 | 0.74% |
| Franklin Resources Inc | 1,635,520 | 1.85% | $44.13M | −149,142 | 0.01% |
| Andera Partners | 1,591,917 | 1.80% | $42.95M | – | 20.80% |
| Geode Capital Management, LLC | 1,584,326 | 1.79% | $42.75M | +283,191 | 0.00% |
| Sr One Capital Management, LP | 1,563,966 | 1.77% | $42.20M | – | 4.06% |
| Bank Of America Corp /De/ | 1,505,547 | 1.70% | $40.62M | +405,175 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 226 | 100M | 100.0% | 36 / 90 | 65 / 22 | 26M | 16M |
| Q1 2026 | 215 | 91M | 100.0% | 33 / 98 | 52 / 38 | 18M | 12M |
| Q4 2025 | 223 | 88M | 100.0% | 52 / 82 | 72 / 20 | 23M | 14M |
| Q3 2025 | 193 | 80M | 89.9% | 43 / 68 | 63 / 15 | 23M | 10M |
| Q2 2025 | 165 | 66M | 74.3% | 42 / 75 | 30 / 24 | 12M | 7M |
| Q1 2025 | 148 | 61M | 68.8% | 54 / 53 | 26 / 13 | 20M | 6M |
| Q4 2024 | 108 | 46M | 52.6% | 16 / 44 | 17 / 14 | 4M | 2M |
| Q3 2024 | 106 | 44M | 50.2% | 19 / 36 | 23 / 6 | 5M | 3M |
| Q2 2024 | 94 | 45M | 50.6% | 14 / 48 | 13 / 12 | 6M | 4M |
| Q1 2024 | 92 | 43M | 48.6% | 17 / 25 | 33 / 12 | 11M | 3M |
| Q4 2023 | 87 | 35M | 39.9% | 23 / 36 | 14 / 12 | 13M | 4M |
| Q3 2023 | 77 | 27M | 30.0% | 22 / 28 | 11 / 13 | 4M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of MLYS | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,820,768 | 3.19% | $76.10M | 0.71% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,968,124 | 2.23% | $53.10M | 0.00% | Jun 30, 2026 |
| SMALLCAP World Fund Inc | 1,652,360 | 1.87% | $44.58M | 0.05% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,495,279 | 1.69% | $40.34M | 0.05% | Jun 30, 2026 |
| Select Health Care Portfolio | 1,180,000 | 1.33% | $37.17M | 0.64% | May 31, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 828,597 | 0.94% | $22.36M | 0.15% | Jun 30, 2026 |
| Small Cap Growth Fund | 792,377 | 0.90% | $20.22M | 0.36% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 728,429 | 0.82% | $19.65M | 0.02% | Jun 30, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 630,000 | 0.71% | $19.85M | 0.01% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 627,892 | 0.71% | $16.02M | 0.05% | Jul 31, 2026 |
| Fidelity Advisor Health Care Fund | 600,000 | 0.68% | $15.31M | 0.49% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 538,986 | 0.61% | $14.54M | 0.09% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 538,629 | 0.61% | $14.53M | 0.15% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 533,511 | 0.60% | $13.62M | 1.18% | Jul 31, 2026 |
| PGIM Jennison Health Sciences Fund | 459,547 | 0.52% | $14.48M | 1.04% | May 29, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jon Congleton | Chief Executive Officer, Director | 603,621 | 0.68% | Jul 15, 2026 |
| Eric Warren | Chief Commercial Officer | 45,838 | 0.05% | Sep 22, 2026 |
| James J. Ferguson III | Chief Medical Officer | 102,400 | 0.12% | Aug 12, 2026 |
| David Malcom Rodman | Chief Medical Officer | 51,384 | 0.06% | Aug 12, 2026 |
| Adam Scott Levy | CFO and Secretary | 48,538 | 0.05% | Feb 20, 2026 |
| Brian Taylor Slingsby | Director | 7,811,918 | 8.84% | Sep 24, 2026 |
| Daphne Karydas | Director | 6,200 | 0.01% | Sep 17, 2026 |
| Capital Healthcare Fund LP RA | Director | 1,873,429 | 2.12% | Mar 31, 2026 |
| Rajeev M. Shah | Director | 5,825,521 | 6.59% | Mar 31, 2026 |
| RA Capital Nexus Fund III, L.P. | Director | 4,280,051 | 4.84% | Mar 31, 2026 |
| Peter Kolchinsky | Director | – | – | Mar 31, 2026 |
| Ra Capital Management, L.P. | Director | 5,456,521 | 6.17% | Mar 31, 2026 |
| Glenn Sblendorio | Director | 6,200 | 0.01% | Feb 20, 2026 |
| Derek DiRocco | Director | 6,200 | 0.01% | Feb 20, 2026 |
| Alexander M. Gold | Director | 6,200 | 0.01% | Feb 20, 2026 |
| Srinivas Akkaraju | Director, 10% owner | 5,877,218 | 6.65% | Feb 20, 2026 |
| Catalys Pacific Fund, LP | 10% owner | 7,903,838 | 8.94% | Nov 21, 2025 |
| Samsara BioCapital GP, LLC | 10% owner | – | – | Mar 17, 2025 |
| Samsara BioCapital, L.P. | 10% owner | 5,674,916 | 6.42% | Mar 17, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Brian Taylor Slingsby Director | Sep 22, 2026 | Sale | −104,320 | $28.81 | $3.01M | 7,805,718 |
| Eric Warren Chief Commercial Officer | Sep 21, 2026 | Option exercise | +7,438 | $13.24 | $98.48K | 45,838 |
| Eric Warren Chief Commercial Officer | Sep 21, 2026 | Sale(10b5-1 plan) | −7,438 | $28.12 | $209.16K | 38,400 |
| Daphne Karydas Director | Sep 15, 2026 | Sale(10b5-1 plan) | −3,000 | $28.58 | $85.74K | 6,200 |
| Daphne Karydas Director | Sep 15, 2026 | Option exercise | +3,000 | $12.02 | $36.06K | 9,200 |
| Eric Warren Chief Commercial Officer | Aug 21, 2026 | Sale(10b5-1 plan) | −7,437 | $25.98 | $193.21K | 38,400 |
| Eric Warren Chief Commercial Officer | Aug 21, 2026 | Option exercise | +7,437 | $13.24 | $98.47K | 45,837 |
| James J. Ferguson III Chief Medical Officer | Aug 10, 2026 | Award | +102,400 | – | – | 102,400 |
| David Malcom Rodman Chief Medical Officer | Aug 10, 2026 | Sale(10b5-1 plan) | −2,170 | $27.09 | $58.79K | 51,384 |
| David Malcom Rodman Chief Medical Officer | Aug 10, 2026 | Option exercise | +2,170 | $16.00 | $34.72K | 53,554 |
| Eric Warren Chief Commercial Officer | Jul 21, 2026 | Option exercise | +7,438 | $13.24 | $98.48K | 45,838 |
| Eric Warren Chief Commercial Officer | Jul 21, 2026 | Sale(10b5-1 plan) | −7,438 | $26.87 | $199.86K | 38,400 |
| David Malcom Rodman Chief Medical Officer | Jul 17, 2026 | Sale(10b5-1 plan) | −416 | $26.53 | $11.04K | 51,384 |
| David Malcom Rodman Chief Medical Officer | Jul 17, 2026 | Option exercise | +416 | $15.44 | $6.42K | 51,800 |
| David Malcom Rodman Chief Medical Officer | Jul 15, 2026 | Sale(10b5-1 plan) | −6,349 | $26.61 | $168.95K | 51,384 |
| David Malcom Rodman Chief Medical Officer | Jul 13, 2026 | Option exercise | +6,349 | $1.08 | $6.86K | 71,791 |
| David Malcom Rodman Chief Medical Officer | Jul 13, 2026 | Option exercise | +3,542 | $10.20 | $36.13K | 61,275 |
| David Malcom Rodman Chief Medical Officer | Jul 13, 2026 | Sale(10b5-1 plan) | −14,058 | $27.58 | $387.72K | 57,733 |
| David Malcom Rodman Chief Medical Officer | Jul 13, 2026 | Option exercise | +4,167 | $14.25 | $59.38K | 65,442 |
| Jon Congleton Chief Executive Officer, Director | Jul 13, 2026 | Sale(10b5-1 plan) | −10,700 | $27.24 | $291.47K | 603,621 |
| David Malcom Rodman Chief Medical Officer | Jul 9, 2026 | Sale(10b5-1 plan) | −2,171 | $30.30 | $65.78K | 57,733 |
| David Malcom Rodman Chief Medical Officer | Jul 9, 2026 | Option exercise | +2,171 | $16.00 | $34.74K | 59,904 |
| Jon Congleton Chief Executive Officer, Director | Jun 30, 2026 | Sale(10b5-1 plan) | −58,000 | $25.94 | $1.50M | 631,321 |
| Jon Congleton Chief Executive Officer, Director | Jun 30, 2026 | Sale(10b5-1 plan) | −17,000 | $26.82 | $455.94K | 614,321 |
| Eric Warren Chief Commercial Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −104,124 | $25.90 | $2.70M | 38,400 |
| Eric Warren Chief Commercial Officer | Jun 26, 2026 | Option exercise | +104,124 | $13.24 | $1.38M | 142,524 |
| David Malcom Rodman Chief Medical Officer | Jun 17, 2026 | Option exercise | +4,167 | $14.25 | $59.38K | 61,262 |
| David Malcom Rodman Chief Medical Officer | Jun 17, 2026 | Sale(10b5-1 plan) | −4,584 | $25.00 | $114.60K | 57,095 |
| David Malcom Rodman Chief Medical Officer | Jun 17, 2026 | Option exercise | +417 | $15.44 | $6.44K | 61,679 |
| Daphne Karydas Director | Jun 17, 2026 | Sale(10b5-1 plan) | −3,000 | $25.00 | $75.00K | 6,200 |
| Daphne Karydas Director | Jun 17, 2026 | Option exercise | +3,000 | $12.02 | $36.06K | 9,200 |
| David Malcom Rodman Chief Medical Officer | Jun 15, 2026 | Sale(10b5-1 plan) | −9,890 | $23.81 | $235.48K | 57,095 |
| David Malcom Rodman Chief Medical Officer | Jun 15, 2026 | Option exercise | +3,542 | $10.20 | $36.13K | 66,985 |
| David Malcom Rodman Chief Medical Officer | Jun 12, 2026 | Option exercise | +6,349 | $1.08 | $6.86K | 69,792 |
| David Malcom Rodman Chief Medical Officer | Jun 12, 2026 | Sale(10b5-1 plan) | −6,349 | $23.93 | $151.93K | 63,443 |
| David Malcom Rodman Chief Medical Officer | Jun 10, 2026 | Option exercise | +2,170 | $16.00 | $34.72K | 65,613 |
| David Malcom Rodman Chief Medical Officer | Jun 10, 2026 | Sale(10b5-1 plan) | −2,170 | $25.00 | $54.25K | 63,443 |
| David Malcom Rodman Chief Medical Officer | May 18, 2026 | Sale(10b5-1 plan) | −417 | $27.55 | $11.49K | 63,443 |
| David Malcom Rodman Chief Medical Officer | May 18, 2026 | Option exercise | +417 | $15.44 | $6.44K | 63,860 |
| David Malcom Rodman Chief Medical Officer | May 13, 2026 | Sale(10b5-1 plan) | −14,056 | $28.58 | $401.72K | 63,443 |
| David Malcom Rodman Chief Medical Officer | May 13, 2026 | Option exercise | +3,541 | $10.20 | $36.12K | 73,333 |
| David Malcom Rodman Chief Medical Officer | May 13, 2026 | Option exercise | +4,166 | $14.25 | $59.37K | 77,499 |
| David Malcom Rodman Chief Medical Officer | May 12, 2026 | Sale(10b5-1 plan) | −6,348 | $29.36 | $186.38K | 69,792 |
| David Malcom Rodman Chief Medical Officer | May 12, 2026 | Option exercise | +6,348 | $1.08 | $6.86K | 76,140 |
| David Malcom Rodman Chief Medical Officer | May 11, 2026 | Option exercise | +2,171 | $16.00 | $34.74K | 71,963 |
| David Malcom Rodman Chief Medical Officer | May 11, 2026 | Sale(10b5-1 plan) | −2,171 | $29.71 | $64.50K | 69,792 |
| David Malcom Rodman Chief Medical Officer | Apr 17, 2026 | Option exercise | +416 | $15.44 | $6.42K | 70,208 |
| David Malcom Rodman Chief Medical Officer | Apr 17, 2026 | Sale(10b5-1 plan) | −416 | $31.33 | $13.03K | 69,792 |
| David Malcom Rodman Chief Medical Officer | Apr 15, 2026 | Sale(10b5-1 plan) | −6,348 | $27.66 | $175.59K | 69,792 |
| Jon Congleton Chief Executive Officer, Director | Apr 13, 2026 | Sale(10b5-1 plan) | −15,730 | $26.83 | $422.04K | 689,321 |
| David Malcom Rodman Chief Medical Officer | Apr 13, 2026 | Option exercise | +4,167 | $14.25 | $59.38K | 90,198 |
| David Malcom Rodman Chief Medical Officer | Apr 13, 2026 | Sale(10b5-1 plan) | −14,058 | $26.54 | $373.10K | 76,140 |
| David Malcom Rodman Chief Medical Officer | Apr 13, 2026 | Option exercise | +6,349 | $1.08 | $6.86K | 82,489 |
| David Malcom Rodman Chief Medical Officer | Apr 13, 2026 | Option exercise | +3,542 | $10.20 | $36.13K | 86,031 |
| David Malcom Rodman Chief Medical Officer | Apr 9, 2026 | Sale(10b5-1 plan) | −2,170 | $27.38 | $59.41K | 76,140 |
| David Malcom Rodman Chief Medical Officer | Apr 9, 2026 | Option exercise | +2,170 | $16.00 | $34.72K | 78,310 |
| Daphne Karydas Director | Mar 31, 2026 | Sale(10b5-1 plan) | −3,000 | $25.00 | $75.00K | 6,200 |
| Daphne Karydas Director | Mar 31, 2026 | Option exercise | +3,000 | $12.02 | $36.06K | 9,200 |
| Jon Congleton Chief Executive Officer, Director | Mar 31, 2026 | Sale(10b5-1 plan) | −55,183 | $26.54 | $1.46M | 705,504 |
| Jon Congleton Chief Executive Officer, Director | Mar 31, 2026 | Sale(10b5-1 plan) | −453 | $27.05 | $12.25K | 705,051 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| David Malcom Rodman Officer | Oct 13, 2026 | 3,542 | $78.07K | Oct 13, 2026 | Exercise of employee stock options |
| Jon Congleton Officer, Director | Sep 30, 2026 | 75,000 | $1.91M | Sep 30, 2026 | Vesting of Restricted Stock Unit Awards |
| Pacific Fund Lp Catalys Director | Sep 22, 2026 | 104,320 | $3.01M | Sep 22, 2026 | Private Acquisition from Issuer/Affiliate |
| Eric Warren Officer | Sep 21, 2026 | 7,438 | $209.14K | Sep 21, 2026 | Exercise of employee stock options |
| David Malcom Rodman Officer | Sep 17, 2026 | 417 | $11.66K | Sep 17, 2026 | Exercise of employee stock options |
| Daphne Karydas Officer | Sep 15, 2026 | 3,000 | $85.74K | Sep 15, 2026 | Exercise of employee stock options |
| David Malcom Rodman Officer | Sep 14, 2026 | 7,709 | $216.93K | Sep 14, 2026 | Exercise of employee stock options |
| David Malcom Rodman Officer | Sep 9, 2026 | 2,171 | $67.02K | Sep 9, 2026 | Exercise of employee stock options |
| Eric Warren Officer | Aug 21, 2026 | 7,437 | $193.19K | Aug 21, 2026 | Exercise of employee stock options |
| David Malcom Rodman Officer | Aug 17, 2026 | 417 | $10.62K | Aug 17, 2026 | Exercise of employee stock options |
| David Malcom Rodman Officer | Aug 13, 2026 | 14,056 | $372.19K | Aug 13, 2026 | Exercise of employee stock options |
| David Malcom Rodman Officer | Aug 10, 2026 | 2,170 | $58.79K | Aug 10, 2026 | Exercise of employee stock options |
| Eric Warren Officer | Jul 21, 2026 | 7,438 | $199.88K | Jul 21, 2026 | Exercise of employee stock options |
| David Malcom Rodman Officer | Jul 17, 2026 | 416 | $11.02K | Jul 17, 2026 | Exercise of employee stock options |
| David Malcom Rodman Officer | Jul 15, 2026 | 6,349 | $168.95K | Jul 15, 2026 | Exercise of employee stock options |